OM1 Supports 650,000 Patient Real-World Regulatory Submission for FDA Approval of Hologic’s Aptima HPV Assay
OM1 assisted in a large-scale study involving 650,000 patients to provide real-world evidence for the FDA approval of Hologic’s Aptima HPV Assay, which is used for cervical cancer screening.
BOSTON–(BUSINESS WIRE)–OM1 helped power a 650,000-patient real-world evidence study supporting FDA approval of Hologic’s Aptima HPV Assay for cervical cancer screening.